Application of botulinum toxin in pregnancy and its impact on female reproductive health

References

• Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008;14:289–298.
   PubMed Web of Science ®Google Scholar
• Pantano S, Montecucco C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci. 2014;71:793–811.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:717–766.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32:1131–1138.
   PubMed Web of Science ®Google Scholar
• Steeves TD, Day L, Dykeman J, et al. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012;27:1789–1796.
   PubMed Web of Science ®Google Scholar
• Klingelhoefer L, Martino D, Martinez-Martin P, et al. Nonmotor symptoms and focal cervical dystonia: observations from 102 patients. Basal Ganglia. 2014;4:117–120.
   Google Scholar
• Lencer R, Steinlechner S, Stahlberg J, et al. Primary focal dystonia: evidence for distinct neuropsychiatric and person-ality profiles. J Neurol Neurosurg Psychiatry. 2009;80:1176–1179.
   PubMed Web of Science ®Google Scholar
• Novak I, Campbell L, Boyce M, et al. Cerebral palsy institute. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol. 2010;17:94–108.
   PubMed Web of Science ®Google Scholar
• Duane DD. Spasmodic torticollis: clinical and biologic featuresand their implications for focal dystonia. Adv Neurol. 1988;50:473–492.
   PubMedGoogle Scholar
• Buccoliero R, Palmeri S, Malandrini A, et al. A case of dystonia with onset during pregnancy. J Neurol Sci. 2007;260:265–266.
   PubMed Web of Science ®Google Scholar
• Smith MS, Evatt ML. Movement disorders in pregnancy. Neurol Clin. 2004;22:783–798.
   PubMed Web of Science ®Google Scholar
• Cersosimo MG, Bertoti A, Roca CU, et al. Botulinum toxin in a case of hemimasticatory spasm with severe worsening during pregnancy. Clin Neuropharmacol. 2004;27:6–8.
   PubMed Web of Science ®Google Scholar
• Cogen PH, Zimmerman EA. Ovarian steroid hormones and cerebral function. Adv Neurol. 1979;26:123–133.
   PubMedGoogle Scholar
• Hruska RE, Silbergeld EK. Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model. Science. 1980;208:1466–1468.
   PubMed Web of Science ®Google Scholar
• Lal S. Pathophyslology and pharmacotherapy of spasmodic torticollis: a review. Can J Neural Sci. 1979;6:427–435.
   PubMed Web of Science ®Google Scholar
• Bertrand C, Molina-Negro P, Bouvier G, et al. Observations and analysis of results in 131 cases of spasmodic torticollis after selectivedenervation. Appl Neurophysiol. 1987;50:319–323.
   PubMedGoogle Scholar
• Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535–549.
   PubMed Web of Science ®Google Scholar
• Newman WJ, Davis TL, Padaliya BB, et al. Botulinum toxin type A therapy during pregnancy. Mov Disord. 2004;19:1384–1385.
   PubMed Web of Science ®Google Scholar
• Aranda MA, Herranz A, Del Val J, et al. Botulinum toxin A during pregnancy, still a debate. Eur J Neurol. 2012;19:e81–2.
   PubMed Web of Science ®Google Scholar
• Morgan JC, Iyer SS, Moser ET, et al. Botulinum toxin A during pregnancy: a survey of treating physicians. J Neurol Neurosurg Psychiatry. 2006;77:117–119.
   PubMed Web of Science ®Google Scholar
• Krug H, Krause P, Kupsch A. Safe administration of botulinum toxin type A injections during pregnancy: a report of two cases. Mov Disord Clin Pract. 2015;2:187–189.
   PubMed Web of Science ®Google Scholar
• Blanchet PJ, Rompré PH, Lavigne GJ, et al. Oral dyskinesia: a clinical overview. Int J Prosthodont. 2005;18:10–19.
   PubMed Web of Science ®Google Scholar
• Møller E, Bakke M, Dalager T, et al. Oromandibular dystonia involving the lateral pterygoid muscles: four cases with different complexity. Mov Disord. 2007;22:785–790.
   PubMed Web of Science ®Google Scholar
• Bakke M, Larsen BM, Dalager T, et al. Oromandibular dystonia - functional and clinical characteristics: a report on 21 cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:e21–6.
   PubMed Web of Science ®Google Scholar
• Bakke M, Møller E. Oromandibular dystonia. In: Ernberg M, Alstergren P, editors. Clinical cases in orofacial pain. Hobroken: John Wiley & Sons; 2017. p. 236–242.
   Google Scholar
• Balasubramaniam R, Ram S. Orofacial movement disorders. Oral Maxillofac Surg Clin North Am. 2008;20:273–285.
   PubMedGoogle Scholar
• Slaim L, Cohen M, Klap P, et al. Oromandibular dystonia: demographics and clinical data from 240 patients. J Mov Disord. 2018;11:78–81.
   PubMed Web of Science ®Google Scholar
• Bakke M, Baram S, Dalager T, et al. Oromandibular dystonia, mental distress and orofacial dysfunction - a follow-up 8-10 years after start of treatment with botulinum toxin. J Oral Rehabil. 2019;46:441–449.
   PubMed Web of Science ®Google Scholar
• Asgeirsson H, Jakobsson F, Hjaltason H, et al. Prevalence study of primary dystonia in Iceland. Mov Disord. 2006;21:293–298.
   PubMed Web of Science ®Google Scholar
• Aronson AE. Clinical Voice Disorders. NY: Thieme Med Publ.; 1985. p. 52–58.
   Google Scholar
• Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol. 2010;17(Suppl 1):28–30.
   PubMed Web of Science ®Google Scholar
• Ankola A, Sulica L, Murry T. Laryngeal dystonia gravidarum: sudden onset of adductor spasmodic dysphonia in pregnancy. Laryngoscope. 2013;123:3127–3130.
   PubMed Web of Science ®Google Scholar
• Adams RJ, Hall HL, Courage ML. Long-term visual pathology in children with significant perinatal complications. Dev Med Child Neurol. 2005;47:598–602.
   PubMed Web of Science ®Google Scholar
• Donnelly UM, Stewart NM, Hollinger M. Prevalence and outcomes of childhood visual disorders. Ophthalmic Epidemiol. 2005;12:243–250.
   PubMed Web of Science ®Google Scholar
• Strömland K, Miller MT. Thalidomide embryopathy: revisited 27 years later. Acta Ophthalmol. 1993;71:238–245.
   PubMed Web of Science ®Google Scholar
• Bunting HJ, Dawson EL, Lee JP, et al. Role of inferior rectus botulinum toxin injection in vertical strabismus resulting from orbital pathology. Strabismus. 2013;21:165–168.
   PubMedGoogle Scholar
• Li Yim JF, Weir CR. Botulinum toxin and pregnancy-a cautionary tale. Strabismus. 2010;18:65–66.
   PubMedGoogle Scholar
• Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol. 2005;100:1404–1414.
   PubMed Web of Science ®Google Scholar
• Enestvedt BK, Williams JL, Sonnenberg A. Epidemiology and practice patterns of achalasia in a large multi-centre database. Aliment Pharmacol Ther. 2011;33:1209–1214.
   PubMed Web of Science ®Google Scholar
• Farrukh A, DeCaestecker J, Mayberry JF. An epidemiological study of achalasia among the South Asian population of Leicester, 1986–2005. Dysphagia. 2008;23:161–164.
   PubMed Web of Science ®Google Scholar
• Arber N, Grossman A, Lurie B, et al. Epidemiology of achalasia in central Israel. Rarity of esophageal cancer. Dig Dis Sci. 1993;38:1920–1925.
   PubMed Web of Science ®Google Scholar
• Gennaro N, Portale G, Gallo C, et al. Esophageal achalasia in the Veneto region: epidemiology and treatment. Epidemiology and treatment of achalasia. J Gastrointest Surg. 2011;15:423–428.
   PubMed Web of Science ®Google Scholar
• Kim E, Lee H, Jung HK, et al. Achalasia in Korea: an epidemiologic study using a national healthcare database. J Korean Med Sci. 2014;29:576–580.
   PubMed Web of Science ®Google Scholar
• Mayberry JF, Atkinson M. Incidence of achalasia in New Zealand, 1980–84: an epidemiological study based on hospital discharges. J Gastroenterol Hepatol. 1988;3:247–252.
   Web of Science ®Google Scholar
• Sonnenberg A. Hospitalization for achalasia in the United States 1997–2006. Dig Dis Sci. 2009;54:1680–1685.
   PubMed Web of Science ®Google Scholar
• Ho KY, Tay HH, Kang JY. A prospective study of the clinical features, manometric fndings, incidence and prevalence of achalasia in Singapore. J Gastroenterol Hepatol. 1999;14:791–795.
   PubMed Web of Science ®Google Scholar
• Howard PJ, Maher L, Pryde A, et al. Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh. Gut. 1992;33:1011–1015.
   PubMed Web of Science ®Google Scholar
• Ohno Y, Kawai M, Shibata Y, et al. Esophageal achalasia in pregnancy. Am J Perinatol. 2000;17:53–55.
   PubMed Web of Science ®Google Scholar
• Fiest TC, Foong A, Chokhavatia S. Successful balloon dilation of achalasia during pregnancy. Gastrointest Endosc. 1993;39:810–812.
   PubMed Web of Science ®Google Scholar
• Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am. 2003;32:235–261.
   PubMed Web of Science ®Google Scholar
• Fletcher PR. Acute hiatal hernia with oesophageal perforation following Heller’s operation. Br J Surg. 1978;65:486–488.
   PubMed Web of Science ®Google Scholar
• Ghoshal S, Davies AJ. An unusual case of vomiting and weight loss in pregnancy – Oesophageal achalasia. J Obstetrics Gynaecol. 2007;27:622–623.
   PubMedGoogle Scholar
• Wataganara T, Leelakusolvong S, Sunsaneevithayakul P, et al. Treatment of severe achalasia during pregnancy with esophagoscopic injection of botulinum toxin A: a case report. J Perinatol. 2009;29:637–639.
   PubMed Web of Science ®Google Scholar
• Hooft N, Schmidt ES, Bremner RM. Achalasia in pregnancy: botulinum toxin A injection of lower esophageal sphincter. Case Rep Surg. 2015;2015:328970.
   PubMed Web of Science ®Google Scholar
• Holliday N, Baker S. Intrasphincteric botulinum toxin injections to treat achalasia diagnosed in 615 pregnancy: a case report. J Reprod Med. 2016;61:615–617.
   PubMed Web of Science ®Google Scholar
• Auger RG, Litchy WJ, Cascino TL, et al. Hemimasticatory spasm: clinical and electrophysiologic observations. Neurol. 1992;42:2263–2266.
   PubMed Web of Science ®Google Scholar
• Cruccu G, Inghilleri M, Berardelli A, et al. Pathophysiologyof hemimasticatory spasm. J Neurol Neurosurg Psychiatry. 1994;57:43–50.
   PubMed Web of Science ®Google Scholar
• Ebersbach G, Kabus C, Schelosky L, et al. Hemimasticatory spasm in hemifacial atrophy: diagnostic and therapeutic aspects in two patients. Mov Disord. 1995;10:504–507.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Carroll WM. Hemimasticatory spasm–aperipheral paroxysmal cranial neuropathy? J Neurol Neurosurg Psychiatry. 1983;46:274–276.
   PubMed Web of Science ®Google Scholar
• Lagueny A, Deliac MM, Julien J, et al. Jaw closing spasm—a form of focal dystonia? An electrophysiological study. J Neurol Neurosurg Psychiatry. 1989;52:652–656.
   PubMed Web of Science ®Google Scholar
• Cersósimo MG, Bertoti A, Roca CU, et al. Botulinum toxin in case of hemimasticatory spasm with severe worsening during pregnancy. Clin Neuropharmacol. 2004;27:6–8.
   PubMed Web of Science ®Google Scholar
• Mir P, Gilio F, Edwards M, et al. Alteration of central motor excitability in a patient with hemimasticatory spasm after treatment with botulinum toxin injections. Mov Disord. 2006;21:73–78.
   PubMed Web of Science ®Google Scholar
• Teive HA, Piovesan EJ, Germiniani FM, et al. Hemimasticatory spasm treated with botulinum toxin: case report. Arq Neuropsiquiatr. 2002;60:288–289.
   PubMed Web of Science ®Google Scholar
• Yan KK, Wei JB, Lin W, et al. Hemimasticatory spasm with single venous compression treated with microvascular decompression of the trigeminal motor rootlet. World Neurosurg. 2017;104:1050.e19-22.
   Web of Science ®Google Scholar
• Mathias S, Kupperman M, Liberman R, et al. Chronic pelvic pain: prevalence, health related quality and economic correlates. Obstet Gynecol. 1996;87:321–327.
   PubMed Web of Science ®Google Scholar
• Abbott JA, Jarvis SK, Lyons SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108:915–923.
   PubMed Web of Science ®Google Scholar
• Abbott J. Gynecological indications for the use of botulinum toxin in women with chronic pelvic pain. Toxicon. 2009;54:647–653.
   PubMed Web of Science ®Google Scholar
• Menendez C. Analysis of the reasons for visits to a neurology office in Asturias. Neurologia. 2009;2:309–314.
   Google Scholar
• MacGregor E. Headache in pregnancy. Neurol Clin. 2012;30:835–866.
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Zwart JA, Hagen K, et al. Epidemiology of headache in Europe. Eur J Neurol. 2006;13:333–345.
   PubMed Web of Science ®Google Scholar
• Peng W, Lauche R, Frawley J, et al. Utilization of complementary and alternative medicine and conventional medicine for headache or migraine during pregnancy: A cross-sectional survey of 1,835 pregnant women. Complement Ther Med. 2018;41:192–195.
   PubMed Web of Science ®Google Scholar
• Amundsen S, Nordeng H, Nezvalova-Henriksen K, et al. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol. 2015;11:209–219.
   PubMed Web of Science ®Google Scholar
• Wabnitz A, Bushnell C. Migraine, cardiovascular disease, and stroke during pregnancy: systematic review of the literature. Cephalalgia. 2015;35:132–139.
   PubMed Web of Science ®Google Scholar
• Chen HM, Chen SF, Chen YH, et al. Increased risk of adverse pregnancy outcomes for women with migraines: a nationwide population-based study. Cephalalgia. 2010;30:433–438.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Sex hormones and headache. Rev Neurol (Paris). 2000;156(Suppl 4):4S30–41.
   PubMedGoogle Scholar
• Turner DP, Smitherman TA, Eisenach JC, et al. Predictors of headache before, during, and after pregnancy: a cohort study. Headache. 2012;52:348–362.
   PubMed Web of Science ®Google Scholar
• Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53:427–436.
   PubMed Web of Science ®Google Scholar
• Harris GE, Wood M, Eberhard-Gran M, et al. Patterns and predictors of analgesic use in pregnancy: a longitudinal drug utilization study with special focus on women with migraine. BMC Pregnancy Childbirth. 2017;17:224.
   PubMed Web of Science ®Google Scholar
• Binder W, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an openlabel study. Otolaryngol Head Neck Surg. 2000;123:669–676.
   PubMed Web of Science ®Google Scholar
• Bruloy E, Sinna R, Grolleau JL, et al. Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plast Reconstr Surg. 2019;143:239–250.
   PubMed Web of Science ®Google Scholar
• Robinson AY, Grogan PM. OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report. Mil Med. 2014;179:e703–4.
   PubMedGoogle Scholar
• Botox cosmetic [product monograph]. Irvine, CA: Allergan Inc; 2011.
   Google Scholar
• Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet. 1995;28:235–269.
   PubMed Web of Science ®Google Scholar
• Hildebrand GJ, Lamanna C, Heckly RJ. Distribution and particle size of type A botulinum toxin in body fluids of intravenously injected rabbits. Proc Soc Exp Biol Med. 1961;107:284–289.
   Web of Science ®Google Scholar
• Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology. 1986;36:545–547.
   PubMed Web of Science ®Google Scholar
• Lange DJ, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve. 1987;10:552–555.
   PubMed Web of Science ®Google Scholar
• Roche N, Schnitzler A, Genet FF, et al. Undesirable distant effects following botulinum toxin type A injection. Clin Neuropharmacol. 2008;31:272–280.
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Aoki KR, Dolly JO, et al. Intramuscular injection of 125Ibotulinum neurotoxin-complex versus 125I-botulinum–free neurotoxin: time course of tissue distribution. Toxicon. 2003;42:461–469.
   PubMed Web of Science ®Google Scholar
• Fertl E, Schnider P, Schneider B, et al. Remote effects of chronic botulinum toxin treatment: electrophysiologic results do not indicate subclinical remodeling of noninjected muscles. Eur Neurol. 2000;44:139–143.
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF, Jankovic J, Feld J. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013;24:298–306.
   PubMed Web of Science ®Google Scholar
• Tan M, Kim E, Koren G, et al. Botulinum toxin type A in pregnancy. Can Fam Physician. 2013;59:1183–1184.
   PubMed Web of Science ®Google Scholar
• Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf. 2016;25:179–187.
   PubMed Web of Science ®Google Scholar
• Badell ML, Rimawi BH, Rao AK, et al. Botulism during pregnancy and the postpartum period: a systematic review. Clin Infect Dis. 2017;66(suppl_1):S30–7.
   PubMed Web of Science ®Google Scholar
• St Clair EH, DiLiberti JH, O’Brien ML. Observations of an infant born to a mother with botulism [Letter]. J Pediatr. 1975;87:658.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Type A botulism—Oregon. MMWR. 1973;22:218–223.
   Google Scholar
• Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation. Philadelphia: Lippincott Williams & Wilkins; 2008.
   Google Scholar
• Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidencebased review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2008;70:1699–706a.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gracies JM, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2008;70:1691–8b.
   PubMed Web of Science ®Google Scholar
• Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2008;70:1707–1714.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American academy of neurology. Neurology. 2016;86:1818–1826.
   PubMed Web of Science ®Google Scholar